Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019

We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).

Automated summary

We examined the incidence of invasive fungal infections (IFIs) within the first year of small molecule kinase inhibitor (SMKI) therapy based on administrative data analysis. The occurrence of IFIs ranged from 0.0% to 10.6% depending on the specific SMKI used, with midostaurin showing the highest incidence. Among the 1286 patients treated with ibrutinib, 38 individuals (3.0%) developed IFIs.